IP Library Granted Patent US 10,385,331
Granted Patent B2
US 10,385,331 · App. 15/434,355 · Granted Aug 20, 2019

Magnetic particles with a closed ultrathin silica layer, method for the production thereof and their use

Inventors: Guido Hennig (Köln, DE); Karlheinz Hildenbrand (Krefeld, DE)
Assignee: Siemens Healthcare Diagnostics GmbH
C12N15/1013C12Q1/6806H01F1/01H01F1/36H01F41/005H01F1/112
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,385,331
App. No.
15/434,355
Granted
Aug 20, 2019
Kind
B2
Abstract

A method for producing silicate-containing magnetic particles having a closed and tight silicate layer and high purity. In addition, the novel method prevents an uncontrolled formation of aggregates and clusters of silicates on the magnetite surface, thereby having a positive influence on the properties and biological applications. The method enables depletion of nanoparticulate solid substance particles on the basis of a fractionated centrifugation. The silicate-coated magnetic particles exhibit optimized magnetization and suspension behavior as well as advantageous run-off behavior from plastic surfaces. These highly pure magnetic particles coated with silicon dioxide are preferably used for isolating nucleic acids from cell and tissue samples, whereby the separating out from a sample matrix ensues by means of magnetic fields. The particles are particularly well suited for the automatic purification of nucleic acids, mostly from biological body samples for the purpose of analyzing them with different amplification methods.

Claims (11)

1. A method for purification of nucleic acids from a biological body sample, comprising:

dissolving the biological body sample containing a nucleic acid into a sample solution;

adding silica-coated magnetic particles to the sample solution, the silica-coated magnetic particles comprising a magnetite core and a uniformly thick distribution of a homogenous single to multiple molecular closed and tight silicate layer on the magnetite core, wherein the silicate layer is formed by depositing an initial silicate layer on the magnetite core and continuously diluting the initially-coated magnetite core using cross flow microfiltration at constant volume to reduce a pH value to a neutral pH value, the silicate layer has a thickness of 0.2 nm to 5 nm, and the silica-coated magnetic particles have grain size distribution between 0.1 μm and 1 μm;

incubating the sample solution at a temperature at which the nucleic acid bonds to the silica-coated magnetic particles;

removing constituents not bonded to the silica-coated magnetic particles with the application of a magnetic field to the sample solution;

removing unspecifically bonded molecules from the nucleic acid with the application and removal of a washing buffer;

separating nucleic acid from the silica-coated magnetic particles with the addition of an elution buffer; and

separating eluate with nucleic acid with the application of a magnetic field.

2. The method of claim 1 , wherein the nucleic acids are RNA or DNA.

3. The method of claim 2 , wherein the nucleic acids are RNA of HCV or HIV.

4. The method of claim 3 , wherein the RNA or DNA is from fixed body samples.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2017
From: HENNIG, GUIDO; HILDENBRAND, KARLHEINZ
To: SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS GMBH
Reel/Frame 041276/0376 →
CHANGE OF NAME Recorded Feb 16, 2017
From: SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS GMBH
To: SIEMENS HEALTHCARE DIAGNOSTICS GMBH
Reel/Frame 041736/0334 →
Priority Claims (1)
EP 05013522 · Jun 23, 2005 · regional
Continuity (3)
Division 14626311 · Feb 19, 2015
Continuation 11917922
Related Publication 20170159043A1 · Jun 8, 2017